AI News NQ Analysis

FRONTEO and Astellas Pharma Sign Agreement on Target Molecule Discovery

NQ Score 0/100
N1 Content Completeness 3

AI Summary (NQ-processed)

AI company FRONTEO and Astellas Pharma have signed an agreement regarding target molecule discovery in drug creation. FRONTEO will provide its proprietary specialized AI, 'KIBIT,' to support Astellas Pharma's drug discovery research.

AI Analysis

Frequently Asked Questions

Q: What is the agreement signed between FRONTEO and Astellas Pharma about?
A: The agreement signed between FRONTEO and Astellas Pharma is on target molecule discovery.
Q: What is the name of the proprietary specialized AI used to provide solutions?
A: The proprietary specialized AI used to provide solutions is named 'KIBIT'.
Q: In which four areas does the group provide KIBIT-based solutions requiring expertise?
A: KIBIT-based solutions are provided in life sciences, economic security, business intelligence, and legal tech.
Q: Where is the natural language processing technology of KIBIT patented?
A: The natural language processing technology used by KIBIT is patented in Japan, the United States, and Europe.
Q: What kind of technology maps analysis results and where is it patented?
A: Structuring technology maps analysis results and is patented in both Japan and the United States.